Emicizumab given every four weeks provides adequate bleeding prophylaxis in hemophilia patients, regardless of coagulation factor VIII inhibitor status, ...
Emicizumab given every four weeks provides adequate bleeding prophylaxis in hemophilia patients, regardless of coagulation factor VIII inhibitor status, ...
No comments:
Post a Comment